Rubicon Research acquires US manufacturing facility for USD 2.9 million

Listed Co AcquisitionStrategic Transactions View source PDF

RUBICON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+3.1%1-day move

₹1470.90

prior close

₹1499.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.9+1.5+2.3+0.0+3.1+7.0————————

Up moveDown movePending

AI summary

Rubicon Research's wholly owned subsidiary AdvaGen Holdings acquired a manufacturing facility in East Brunswick, New Jersey from InvaTech Pharma Solutions for USD 2.9 million enterprise value, via a US bankruptcy court Section 363 process. The facility makes oral solid and liquid formulations, has 10+ years of USFDA inspection history, and is similar in size to Rubicon's Satara plant. A May 2026 inspection drew 6 procedural Form 483 observations now addressed. Manufacturing expected to commence in calendar year 2027.

Likely market impact

Gives Rubicon its first US manufacturing footprint and supports specialty product growth. Modest deal size; no product approvals included, so near-term revenue impact limited.